Inventiva S.A.
IVA
Clasificación en acciones
#10161
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Precio por acción
$3.48
Capitalización bursátil
$821.04M
Cambio (1 día)
-0.64%
Cambio (1 año)
-5.88%
País
FR
Comercio Inventiva S.A. (IVA)
Categoría
Healthcare
Historial del precio de la acción de Inventiva S.A. (IVA)
Precio más alto de cierre: $3.42 el 2026-10-01
Precio más bajo de cierre: $11.50 el 2021-08-01
Precio más bajo de cierre: $11.50 el 2021-08-01
Historial del precio de la acción de Inventiva S.A. desde 2021 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 11.32% |
| 2025 | 81.18% |
| 2024 | -45.73% |
| 2023 | -3.30% |
| 2022 | -66.26% |
| 2021 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $536.22 | 25.74% |
US
|
|
| $222.61 | 729.09% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.32 | 7.88% |
NL
|
